{'fraction_non_alphanumeric': 0.045375809609881, 'fraction_numerical': 0.02511673444795903, 'mean_word_length': 4.686723768736616, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 2, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
A Synthetic HIV-1 Subtype C Backbone Generates Comparable PR and RT Resistance Profiles to a Subtype B Backbone in a Recombinant Virus Assay

In order to determine phenotypic protease and reverse transcriptase inhibitor-associated resistance in HIV subtype C virus, we have synthetically constructed an HIV-1 subtype C (HIV-1-C) viral backbone for use in a recombinant virus assay. The in silico designed viral genome was divided into 4 fragments, which were chemically synthesized and joined together by conventional subcloning. Subsequently, gag-protease-reverse-transcriptase (GPRT) fragments from 8 HIV-1 subtype C-infected patient samples were RT-PCR-amplified and cloned into the HIV-1-C backbone (deleted for GPRT) using In-Fusion reagents. Recombinant viruses (1 to 5 per patient sample) were produced in MT4-eGFP cells where cyto-pathogenic effect (CPE), p24 and Viral Load (VL) were monitored. The resulting HIV-1-C recombinant virus stocks (RVS) were added to MT4-eGFP cells in the presence of serial dilutions of antiretroviral drugs (PI, NNRTI, NRTI) to determine the fold-change in IC50 compared to the IC50 of wild-type HIV-1 virus. Additionally, viral RNA was extracted from the HIV-1-C RVS and the amplified GPRT products were used to generate recombinant virus in a subtype B backbone. Phenotypic resistance profiles in a subtype B and subtype C backbone were compared. The following observations were made: i) functional, infectious HIV-1 subtype C viruses were generated, confirmed by VL and p24 measurements; ii) their rate of infection was slower than viruses generated in the subtype B backbone; iii) they did not produce clear CPE in MT4 cells; and iv) drug resistance profiles generated in both backbones were very similar, including re-sensitizing effects like M184V on AZT.


Introduction
Subtype C of the Human Immunodeficiency Virus type 1 (HIV-1) is accountable for over 50% of the HIV-1 infections worldwide [1,2,3,4]. Some authors suggest that the global spread of subtype C might be related to a reduced virulence compared to other subtypes [4]. However, increased tourism to, and migration from, the regions where subtype C is most common, are possibly important factors for an increasing prevalence of subtype C around the world [5,6].
An adequate resistance-profiling tool requires an assay that correctly assesses drug resistance for all HIV variants. This can be a challenge as even quasi-species in a single individual may differ up to 10% [2]. Additionally, in order to generate correct sensitive/ resistant calls, the sequence interpretation algorithm needs to be able to integrate the constantly growing knowledge of resistanceassociated mutations (RAMs). This should also include different possible pathways to anti-retroviral drug resistance among the different subtypes.
The phenotypic anti-HIV drug resistance assay as described by Hertogs et al. [7] is based on HIV-1 subtype B (HXB2), as this was one of the first HIV-1 clones isolated from the DNA of H9 cells infected with HIV-1 IIIB [8]. In that assay, protease and reverse transcriptase sequences from a patient virus are recombined into the subtype B backbone, deleted for the protease and reverse transcriptase sequences, and the recombinant virus is assessed for the existence of resistance to antiretroviral drugs. We wanted to investigate whether this HXB2-based system (HIV-1 subtype B) can be used to assess resistance in protease reverse transcriptase (GPRT) sequences of non-subtype B viruses.
We constructed an HIV-1 subtype C backbone as HIV-1 subtype C is the most prevalent HIV-1 subtype worldwide and therefore an important diagnostic target. Protease-reverse transcriptase amplicons were generated from HIV-1 subtype C-infected patient samples and successfully recombined into the subtype C viral backbone. The resulting viruses allowed to test for drug susceptibility in a subtype C viral context. Subsequently, GPRT amplicons were isolated from these subtype C viruses and recombined into the subtype B backbone. The resulting recombinant virus stocks were again tested for drug susceptibility allowing a comparison of the resistance profiles measured in both HIV subtype backbones.

Samples
Eight HIV-1 clinical plasma samples with homology to subtype C in the gag-protease-reverse transcriptase region (GPRT region) were used. A written informed consent had been obtained for the samples. All samples were anonymised before transfer and use for this study. One sample had no resistance-associated mutation (RAMs) while the remaining 7 samples had at least 8 documented RAMs (range 8-29, Table 1).

Viral RNA extraction
Viral RNA extraction of plasma and virus stocks was carried out on an EasyMAG (bioMérieux, Boxtel, The Netherlands) according to the guidelines of the manufacturer, starting with 600 ml input material and eluting in 25 ml. If the samples were processed for viral load determination on the EasyQ (see below), EasyQ calibrator was added along with the magnetic silica according to the guidelines of the manufacturer.

GPRT amplification and gel analysis
A One-Step RT-PCR amplification (One-Step SuperscriptIII HiFi, Invitrogen, CA, USA) was used to generate a 2.3 kb HIV-1 fragment (containing the downstream part of GAG and about two thirds of the adjacent POL region (Protease, Reverse Transcriptase and part of Integrase)) using the ''39-RT'' (59-catgagaaatatcacagtaattggagagcaatg-39) and ''59-OUT'' (59-gcccctaggaaaaagggctgttgg-39) primers. RNA input was 10 ml, final volume 35 ml. Subsequently, a nested PCR was performed (final volume 50 ml, DNA input 5 ml) using the (a) ''39-In'' (59-ctaggaaaaagggctgttggaaatg-39) and ''59-In'' (59-catctacatagaaggtttctgctcc-39) primers generating a 1.8 kb GPRT fragment for homologous recombination with the subtype B backbone, or (b) the ''59-Infusion'' (59-aatgtggaaaggaaggacaccaaatgaaag-39) and ''39-Infusion'' (59-ctcataaccgttcggtggacctaaggact-39) primers generating a 1.7 kb GPRT-fragment adapted for ''In-Fusion'' cloning in the subtype C backbone (see below). The In-Fusion amplicon is shorter. In contrast to homologous recombination, where the overlaps are preferably as long as possible, the overlapping sequences must be exactly 15 bases long in the In-Fusion assay. Both nested amplicons encode roughly the same region of the 39-end of GAG (from aa31 of p7 onwards) but contain the same coding sequences for protease and reverse transcriptase (400 aa). To ensure identical mutation profiles, all virus stocks were sequenced to ascertain that no other non-subtypespecific mutations might influence the resistance profile (See 2.11).

Amplicon purification
Gel extraction of the 1.7 kb GPRT-In-Fusion amplicons was performed using the QIAquick Gel Extraction Kit (Qiagen), following the manufacturer's instructions. The 1.8 kb GPRT amplicons, used for homologous recombination, were purified prior to gel analysis, using the QIAquick PCR Purification Kit (Qiagen), following the manufacturer's instructions. 5. Design and construction of the HIV-1 subtype C backbone for In-Fusion-cloning 5.1. Initial sequence design, synthesis and construction of the HIV-1 subtype C backbone. The in silico design of the HIV-1 subtype C backbone was based on the subtype C sequence with accession number AB023804 (www.hiv.lanl.gov). This sequence lacked part of the 39LTR region, which was completed by adding the matching bases as present in the 59 LTR (59-GTGGAAAA-TCTCTAGCA-39). A BstEII restriction site present at position 1534 (acaGGTAACCca -coding for Thr-Gly-Asn-Pro in GAG) was changed to ''acaGGGAACCca'' conserving the translation. Also an AccIII restriction site (TCCGGA) at position 308 (59 LTR) was modified to CCCGGA for cloning purposes (see below).

5.2.
Synthetic production of the HIV-1 subtype C backbone. The final design of the subtype C sequence was divided into 4 fragments (flanked by EcoRI and BamHI restriction sites for cloning purposes), three of which were destined for synthesis ( Fig. 1, fragments I, II, III). The synthesis of the 3 DNA fragments was performed at Centocor, CA, USA [9,10] as follows: padded sequences were parsed into contiguous segments of equal length on both the forward and reverse strands; each segment was chemically synthesized as an oligonucleotide using GENEW RITER TM instrumentation (Centocor) and purified by reversed phase HPLC (Dionex, Sunnyvale, CA); purified oligonucleotides were assembled using proprietary gene assembly technology (Centocor, [9,10] and cloned into a pGEM-3z vector (2743 bp) using EcoRI and BamHI (Fig. 1). Vector Fragment-I ( Fig. 1-A) contained an EcoRI-BamHI flanking fragment of HIV-1 59-LTR and GAG, as well as an inserted BstEII restriction site and a small downstream part of POL (2205 bp). Vector Fragment-II ( Fig. 1-B) contained an EcoRI-BamHI flanking fragment of HIV-1 GAG, as well as an inserted BstEII restriction site, the 39 part of POL, a fragment of ENV (mostly deleted and replaced with a NotI-containing sequence) and the 39-LTR (3460 bp). Vector Fragment-III ( Fig. 1-D) contained an EcoRI-BamHI flanking fragment of the complete HIV-1 ENV and the upstream part of the 39LTR (3412 bp). While the V3 envelope region of AB023804 was predicted to be R5-tropic according to the Geno2Pheno prediction tool (http://coreceptor.bioinf.mpi-inf.mpg. de/index.php) and Position Specific Scoring Matrices (PSSM, http://indra.mullins.microbiol. washington.edu), an R4-tropic virus was needed for the transfection assay in MT4 host cells. An envelope sequence retrieved from Los Alamos (subtype C clone C.ZA.01.01ZARP1) was predicted to be X4-tropic and was used to design Vector Fragment-III ( Fig. 1-D) The fragment containing the protease and reverse transcriptase region was not synthesized but PCR-amplified from clinical samples as described above.
5.3. Subcloning of the HIV-1 subtype C backbone. In a first step vector Fragment-I and vector Fragment-II were joined by subcloning the EcoRI-BstEII fragment from Vector Fragment-I in Vector Fragment-II digested with the same enzymes. This resulted in an HIV-1 subtype C clone (Vector Fragment-I-II - Fig. 1-C) that had both the majority of POL (replaced by BstEII) and ENV (replaced by NotI) deleted.
The PacI-AccIII fragment of Vector Fragment-III ( Fig. 1-D) was subcloned in Vector Fragment-I-II ( Fig. 1-C) digested with the same enzymes. This resulted in a Vector Fragment-I-II-III which only had the GPRT region deleted, called ''pGEM-HIV-1-C-Dgprt-BstEII''. Finally, the vector was linearized by BstEII and a small artificial sequence (59-GTCACCGCGTGCGATATCGAGCCCG-39) was inserted transforming the BstEII site into a BstEII-EcoRV-BstEII site, to reduce the background during In-Fusion and transformation into competent cells. This vector was called ''pGEM-HIV-1-C-Dgprt-BstEII-V'' ( Fig. 1-E). The linearized vector enabled In-Fusion cloning with the 1.7 GPRT-In-Fusion patient-derived amplicons, restoring a full genome, infectious HIV-1 clone ( Fig. 1-E, Genbank reference GU474419) (see below). In a phylogenetic tree, the pGEM-HIV-1-C-Dgprt-BstEII-V sequence (completed with a wildtype subtype C GPRT sequence) clustered together with the other HIV-1 subtype C sequences ( Fig. 1-F). 6.2 HIV-1 subtype B backbone. In contrast to the In-Fusion strategy for the subtype C backbone, a homologous recombination event strategy was used for the subtype B backbone to generate infectious virus [7]. Here the BstEII-linearized pGEM-HXB2Dgprt-BstEII backbone was co-transfected with the 1.8 kb Table 1. Overview of the clones per sample, day of harvest (subtype C and B), VL and p24 measurements as well as the corresponding resistance-associated mutations per clone (as referenced by IAS-USA, ANRS) per sample.

Transformation into MAX EfficiencyH Stbl2 TM cells
A total of 10 ml of diluted In-Fusion reaction mix (dilution prepared during In-Fusion cloning -see 2.6.) was added to the MAX EfficiencyH Stbl2 TM cells (Invitrogen, Cat. No. 10268-019) and treated according to the guidelines of the manufacturer. LBampicillin agar plates were incubated at 30uC for approximately 24 hours.

DNA preparation
Overnight liquid LB-ampicillin cultures (3 ml) were prepared from single colonies (n = 8/sample) and DNA was prepared using the PureLink HQ 96 Plasmid DNA Purification Kit (Invitrogen, Cat. No. K2100-96), according to the guidelines of the manufacturer. The plasmid integrity was checked by restriction analysis using NdeI (New England Biolabs) and the resulting full HIV-1-C genome plasmids (n = 1-5 per sample, Table 1) were used for transfection.

Generation of recombinant virus stocks -Antiviral experiment
MT4 cells were transfected using the Amaxa nucleofection technology (Amaxa Biosystems, Cologne, Germany) according to the manufacturer's instruction. For the subtype C full genome plasmids: 10 ml plasmid (1 mg/ml) of the HIV-1 subtype C clones (see 2.8.) was transfected, using pulsation program A-27, into 2.5610 6 MT4-eGFP cells, resuspended in 100 ml solution V. Identical settings were applied for the subtype B transfection but the full genome plasmid was replaced by 1 ml pGEM-HXB2Dgprt-BstEII-linearized plasmid and 9 ml of the 1.8 kb GPRT amplicon (see 2.6.2). Transfected cells were cultured at 37uC and 5% CO2. Infection rate and CPE were monitored on a daily basis until all cells were infected (monitored by eGFP production) or until full cytopathic effect (CPE) was reached after which the recombinant virus was harvested. The resulting virus stocks were titrated and added to MT4-eGFP cells in the presence of serial dilutions of antiretroviral drugs (PI, NNRTI, N(t)RTI) to determine the fold-change in the concentration at which 50% of the virus is inhibited (IC50) compared to the IC50
P24 measurements were performed on the MiniVidas (bioMérieux) using the Vidas P24 II (P24) kit (Cat. nr. 30117, bioMérieux) according to the guidelines of the manufacturer.

Sequencing
Sequencing reactions were performed with the Big Dye Terminator Cycle Sequencing Kit v3.1 (Cat nu. 4337457, Applied Biosystems, CA, USA). The primers used for the sequence confirmation of the pGEM-HIV-1-C-Dgprt-BstEII-V backbone after cloning are listed in Table 2-A, the primers used to sequence the GPRT amplicons are listed in Table 2 The purification was performed using the DyeEX (Qiagen) purification kit, according to the guidelines of the manufacturer.
The ABI3730 XL (Applied Biosystems) performed the sequence detection and analysis was done using ''Seqscape'' (Applied Biosystems software).

Generation of HIV-1 subtype C recombinant virus stocks
A total of 8 different HIV-1 subtype C amplicons were processed according to the scheme depicted in Figure 2. A total of 8 colonies were picked per In-Fusion reaction (1 In-Fusion/ amplicon) and sequenced, to verify a correct insert of the GPRT  sequence. In total, 23 clones bearing resistance mutations, were retained for further processing (Samples 1-7, Table 1). Only one clone of sample 8 (no RAMs, Table 1) was retained and used as a subtype C wild-type reference to calculate fold-changes (see below).

Phenotypic characteristics of HIV-1 subtype C and subtype B recombinant virus stocks
The HIV-1 subtype C virus stock cultures were monitored on a daily basis for spread of infection, viral load (VL) and p24 production ( Table 1). Some viruses replicated very fast and infected almost all cells within 7 days (n = 6, Table 1). A majority however, replicated slowly and needed up to 18 days to infect all cells (average time and standard deviation were 12.25 days 64.07, Table 1). No clear cytopathogenic effect (CPE) was observed among the HIV-1 subtype C-infected cells and hence spread of infection needed to be monitored on the basis of fluorescence. As an example, the complete monitoring of the clones of sample 4 is shown in Fig. 3. Here, a gradual increase of fluorescence in cell clusters could be observed from day 4 ( Fig. 3A -1) over day 6 ( Fig. 3A -2) to the final point on day 11 where the RVS was harvested (Fig. 3A -3). As in the example, harvesting occurred at the moment where nearly all cell clusters were completely fluorescent, which coincided with the moment at which no or a smaller increase in viral load was measured compared to the previous day. Similar curves were observed for p24 measurements.
On average, a 3.02 log 60.61 increase in VL and a 1.94 log 60.42 increase in p24 production was observed (Table 1).
After harvesting the subtype C viruses, RNA was extracted, amplified and recombined into an HIV-1 subtype B backbone. The resulting recombinant viruses were sequenced to ensure a complete mutation analysis of the GPRT region (Fig. 2). The corresponding HIV-1 subtype B clones (Fig. 2

Genotypic analysis of HIV-1 GPRT subtype C sequence in the subtype C and subtype B backbones
Identical GPRT sequences (Table 1; Fig. 2, Ia) were found for all virus stocks derived from the same amplicon except for one clone lacking 184V (Sample 3, Clone 3; Table 1). All genotypes remained unaltered during the process of re-culturing in either backbone (Fig. 2, Ib, IIa and IIb).     figure 4. The plots demonstrate an overall similarity in FC between virus stocks generated from a subtype C amplicons recombined in subtype B and a subtype C backbone for all drug classes (Fig. 4-A, B, C, D). Correlations were high and very similar among the three drug classes: R 2 = 0.88 (Fig. 4-A, all drug classes), 0.88 ( Fig. 4-B, NRTI), 0.90 ( Fig. 4-C, NNRTI) and 0.87 ( Fig. 4-D, PI). The FC of the samples analyzed covered the entire resistance spectrum from virus fully susceptible to fully resistant to one or more drugs. The ratio FC Subtype B /FC Subtype C for most drugs was close to one ( Fig. 4-E), indicating that the observed fold-change values of the GPRT amplicons in the subtype C backbone were very similar to the FC observed for that same amplicons in the subtype B backbone. However, some differences were observed. The FC ratio was significantly different from 1 (p,0.05) for emtricitabine (FTC, p = 0.031), nevirapine (NVP, p = 0.043), etravirine (ETR, p = 0.033), lopinavir (LPV, p = 0.0041) and darunavir (DRV, p = 0.002). The ratios for FTC (0.50) and ETR (0.67) suggest that, for these drugs, the FC in the subtype C backbone is higher than in the subtype B backbone, whereas for nevirapine (1.61), lopinavir (1.86) and darunavir (1.78) the opposite is observed (Fig. 4-E).

Single mutation effects on FC
Clone 3 of Sample 3 (Table 1) enabled us to investigate the effect of a single RAM (M184V in RT) on the FC of viruses with the subtype C GPRT sequence inserted in the HIV-1 Subtype B and C backbones. In RT, a change at position 184 from methionine to valine results in an increase in FC for 3TC [11,12] and FTC [13] while it decreases the FC for AZT, d4T and TDF [14]. This effect was observed with both types of backbone as shown in Fig. 5. The increase in FC is most pronounced and highly significant (p = ,0.0001) for both 3TC and FTC and for both subtype backbones. The resensitizing effect for AZT was highly significant (p,0.0001) in both subtype backbones while it was significant (p,0.05) only in the subtype C backbone for d4T (p C = 0.046; p B = 0.2576) and TDF (p C = 0.0267; p B = 0.1257). FCs for ddI and ABC were not significantly affected by the presence of 184V.

Discussion
Synthetic biology enabled the construction of a fully replicating, infectious HIV-1 subtype C virus starting from an in silico design. Although promising, this approach is still in its infancy and only achieved at a relatively high cost, especially when whole functional systems are constructed [15,16,17,18,19]. This is true even for ''simple/small'' genomes like HIV-1. Nevertheless the expectations for Synthetic Biology go much further, evidenced by the BioBrick Foundation (www.biobricks.org), the iGEM competition (2010.igem.org) and several minimal genome projects [20,21,22,23] aimed at generating a suitable chassis. We were interested in creating an HIV subtype C backbone to verify the validity of the resistance predictions performed on non-subtype B amplicons in a routine setting. As suggested by Church [24], safety and control were key operating factors and hence, the idea of creating a synthetic virus was presented to an international ethics committee that gave several recommendations. The committee concluded that identical safety measures applied to this work as to any other (research) work performed on viruses in our laboratories and that any findings needed to be reported. The committee further recommended that each research step should be carefully monitored, assessed and documented in order to (proactively) contain and resolve any possible issues.
Although the synthetic construction of the subtype C backbone might be a first for HIV, the first virus constructed in the absence of natural template was the polio virus in 2002 [25], followed in the next year by the assembly of the complete infectious genome of bacteriophage_X174 (5,386 bp) from a single pool of chemically synthesized oligonucleotides [19]. Currently larger projects are still ongoing, mostly referred to as ''minimal genome'' projects as discussed in Rabinow et al. [26] and Gibson et al. [23].
The aim of this study was to investigate whether the drug resistance profile of an HIV-1 subtype C GPRT amplicon is correctly assessed when introduced into an HIV-1 subtype B backbone.
To generate a unique set of fully characterized HIV-1 subtype C viruses for our study, we chose for a clonal approach by amplifying subtype C GPRT sequences from patient samples infected with HIV-1 subtype C and cloning these sequences by In-Fusion into our HIV-1 subtype C backbone. There are multiple reasons for the decision not to generate virus directly from patient samples: (a) these assays are often performed on freshly isolated donor lymphocytes [27] and we had only access to frozen plasma samples; (b) the isolation and culturing of virus from these lymphocytes is time-consuming and very labor-intensive and (c) the prolonged culture times of this kind of assay have been shown to select for subpopulations of HIV-1 variants [28] which could influence the drug susceptibility profile. Additionally, these patients have received Highly Active Anti-Retroviral Therapy (HAART) and therefore might have a rather wide range of different quasi-species, hence the clonal approach ensured a strict selection of mutations and allowed a focused resistance profiling in the subtype C background.
A recombinant virus assay strategy was used for the HIV-1 subtype B virus generation. In essence, this generated the same result as the clonal In-Fusion strategy, but is faster since the transformational step in E. coli (required to make a selection of mutations from the pool of quasi-species) could be omitted. To ensure that identical mutations were present in both backbones, the recombinant subtype B viruses were sequenced to control that no other non-subtype-specific mutations might influence the resistance profiling.
The HIV-1 subtype C backbone construct was made similar to the construct described by Hertogs et al. [7]. Both backbones generated X4 viruses (required for MT4 infection) and have the same regions deleted for insertion of identical GPRT amplicons. The clonal approach allowed selection of identical viral protease and reverse transcriptase sequences among clones derived from each sample. Functionality of the viral constructs (virus production) was primarily illustrated by spread of infection (monitored by CPE and fluorescence), and supported by the P24 and viral load increase. However, the nature of this cell-based assay makes a linear comparison between viral titer, viral load and P24 content impossible as investigated by Marozsan et al. [29]. Direct comparisons are impossible because P24 and viral load assays can only measure increase or decrease of targets, but cannot differentiate between functional and non-functional virions (hence free or incorporated RNA or P24).
Differences observed during culturing were clear (slower infection rates and nearly no CPE in subtype C viruses as compared to subtype B viruses) and are most probably due to the subtype-specific characteristics of the HIV-1 subtype C virus, which have also been observed and described by other authors [30,31]. In fact, the observation of these subtype-related differences in our synthetic viruses, only strengthens the validity of our resistance profiling experiment as they show that our synthetic viruses behave in a similar fashion to naturally occurring HIV-1 subtype C viruses that have been studied.
The remaining question is whether HAART resistance profiles of GPRT are comparable between HIV-1 subtype B and subtype C, even if both seem to have clearly different viral kinetics e.g. regarding CPE. Directly related to this, is the obvious question whether resistance profiling of a subtype C GPRT sequence in a subtype B backbone is feasible. If differences were observed, this could have far-reaching diagnostic consequences.
This first exploratory study indicates that there were no differences in FC between phenotypic resistance assessed in the subtype B and C backbones for 13 out of the 18 drugs tested. For FTC, NVP and ETR the differences were close to the significance level of p = 0.05, whereas highly significant (p,0.05) differences were observed for LPV and DRV. While the FC in subtype C backbone seemed to be higher compared to the B backbone for FTC (ratio B/C = 0.50) and ETR (ratio B/C = 0.67), the opposite was found for NVP (ratio B/ C = 1.61), LPV (ratio B/C = 1.86) and DRV (ratio B/C = 1.78). As this was a proof of concept study, the number of tested samples was limited. An analysis of a greater number of clinical HIV-1 subtype C samples is ongoing and will confirm whether the trends observed for these drugs are indeed significant.
With respect to the effect of individual mutations, FC is affected in similar ways in both subtypes as demonstrated in the analysis of the M184V mutation (increase in FC for 3TC and FTC, resensitization for AZT, d4T, TFV).
In conclusion, we successfully constructed a synthetic HIV-1 subtype C backbone for a recombinant virus phenotyping assay. The resulting recombinant subtype C viruses seemed less virulent compared to subtype B (e.g., no CPE) as has been observed in previous HIV-1 subtype C viral studies, but the generated resistance profiles were similar compared to the profiles obtained in an HIV-1 subtype B backbone for the majority of the drugs.